Larazotide (AT-1001)

What is larazotide?

Larazotide (AT-1001) is the most clinically studied compound specifically targeting intestinal tight junctions — the molecular seals between intestinal epithelial cells that determine what passes from the gut lumen into the bloodstream. When tight junctions are disrupted, larger molecules including food antigens, bacterial endotoxins (LPS), and inflammatory compounds cross into circulation — a state commonly called 'leaky gut,' or more precisely, increased intestinal permeability. Larazotide was designed to stabilize tight junctions by blocking the zonulin pathway that opens them.

The zonulin pathway discovery by Alessio Fasano is the mechanistic foundation. Fasano identified zonulin — a protein produced by intestinal epithelial cells in response to certain stimuli (gluten, bacteria) — as the physiological regulator of tight junction permeability. Larazotide was derived from the receptor-binding domain of Zot (a bacterial toxin that hijacks the zonulin receptor) and modified to block rather than activate the receptor.

Phase II celiac trials showed larazotide significantly reduced intestinal permeability (lactulose/mannitol ratio), improved GI symptom scores, and reduced celiac-related autoimmune markers vs. placebo. Phase III data was mixed on primary endpoints but the mechanistic permeability reduction held. For biohackers, larazotide is the most evidence-based option for tight junction integrity — more mechanistically targeted than BPC-157's general gut healing.

How it works

Tight Junction Biology

Intestinal epithelial cells are sealed by tight junction protein complexes — primarily claudins, occludin, and ZO (zonula occludens) proteins. These form a paracellular barrier controlling what passes between cells. In healthy intestine, tight junctions allow water and small molecules to pass while blocking larger molecules. When disrupted, the barrier becomes permeable to food antigens, LPS (bacterial endotoxin), and other immune-activating molecules.

Zonulin Pathway Antagonism

Zonulin is the primary physiological regulator of tight junction opening. It signals through EGFR → PKCα/Src → phosphorylation of ZO-1 and occludin → tight junction disassembly. Larazotide competitively blocks zonulin receptor binding, preventing EGFR activation and the downstream signaling that opens tight junctions. This is a highly targeted mechanism — blocking one specific signal rather than broadly suppressing inflammation.

Oral Local Action — A Key Practical Advantage

Larazotide is designed for local gut action — it doesn't need to be systemically absorbed to work. It acts on the luminal surface of intestinal epithelial cells where zonulin receptors are expressed. This local action avoids systemic exposure and side effects while targeting exactly where gut permeability is determined. It's also why oral larazotide has a different bioavailability profile from other peptides — systemic absorption is not the goal.

What the research shows

Community knowledge

Larazotide's community spans celiac patients (with the most clinical data), people with non-celiac gluten sensitivity, and the broader leaky gut biohacker community. Consistently reported: reduced bloating, cramping, and diarrhea consistent with Phase II data; improved food reactions (fewer reactions to trigger foods while on protocol); and the BPC-157 stack combination — BPC-157 for mucosal repair, larazotide for tight junction permeability specifically. Accessible oral dosing is a significant practical advantage over injectable gut peptides.